Molina Clinical Policy
Microwave Ablation Thermotherapy for Breast Cancer: Policy No. 381

Last Approval: 08/14/2024
Next Review Due By: August 2025

DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment, and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

OVERVIEW

Breast cancer accounts for over two million malignancy cases a year globally and is the second leading cause of cancer death in women of the United States. Since 1975 breast cancer mortality has reduced by over 50% due to improvements in screening, treatment of early breast cancer, and overall treatment of metastatic breast cancer. Screening and early recognition is imperative in the prognosis of breast cancer patients. There are a myriad of ways to treat breast cancer that include surgery, chemotherapy, radiation, and ablative therapies (Taghian and Merajver 2024; Joe 2023).

Microwave ablation (MWA), sometimes referred to as focused microwave thermotherapy (FMT), is a local hyperthermic ablative therapy that treats primary breast cancer with focused microwaves based on the theory that heat can destroy microscopic carcinoma cells in the breast and reduce cancer recurrence. MWA utilizes electromagnetic waves to induce localized heating caused by the movement of water molecules. Given that tumor cells have higher water content than the surrounding adipose and breast glandular tissue, this allows the MWA technique to heat and kill the tumor cells while leaving the surrounding healthy tissue largely intact. Inducing tumor necrosis via MWA prior to surgery may improve surgical outcomes and reduce the possibility of inadvertently seeding viable cancer cells during the surgical procedure thus resulting in fewer local recurrences in the breast. In patients with locally advanced primary breast cancer, MWA may sufficiently reduce the size of the tumor to allow a less invasive surgical procedure. Furthermore, if a sufficient thermal dose is applied, thermotherapy treatment of early-stage breast cancer may destroy the tumor and eliminate the need for any further breast surgery or radiation therapy. MWA has been investigated in multiple settings, including as a treatment for primary breast cancer in conjunction with lumpectomy for early-stage breast cancer, and as a cytoreductive technique in conjunction with preoperative chemotherapy in locally advanced breast cancer.

Regulatory Status

At this time, there are no FDA approved microwave thermotherapy devices indicated for the treatment of breast cancer on the market.

COVERAGE POLICY

Microwave ablation thermotherapy/Focused microwave thermotherapy as a treatment for breast cancer is considered **experimental, investigational, or unproven** due to insufficient evidence in peer reviewed medical literature that have not established safety, efficacy, and effect on net health outcomes.

DOCUMENTATION REQUIREMENTS. Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

SUMMARY OF MEDICAL EVIDENCE

Zhou et al. (2021) conducted a single arm multicenter clinical study that enrolled 35 participants with early-stage breast cancer. All 35 patients underwent microwave ablation (MWA) therapy prior to surgical resection. Thirteen patients who underwent surgery alone with a diagnosis of breast cancer at a similar stage to the 35 participants were used at the control group. Blood samples were collected before and after MWA or surgery to analyze immune cell populations, serum cytokines, secretory immune checkpoint molecules, and T-cell receptor sequencing. Of the 35 participants, 32 achieved complete tumor ablation. In addition to the ablation, those treated with MWA achieved a significant antitumor immune response that was still present post-surgery.

Yu et al. (2020) conducted a single institution retrospective study comparing nipple sparing mastectomy versus MWA. Twenty-one patients were included in the MWA group, and forty-three patients were in the nipple sparking mastectomy group. All participants in both groups achieved technique effectiveness and there was no significant difference in tumor progression between the two groups. In the MWA group there was one local tumor progression at 42 months post treatment, and one ipsilateral breast recurrence at 28 months post treatment. In the nipple sparing mastectomy group there was one ipsilateral breast recurrence at 31 months post-surgery, and two bone metastases at 30- and 34-months post treatment. Neither group had any cancer related deaths or major complications. The MWA group required less hospital time and achieved better cosmetic results. This study revealed MWA could achieve similar short-term results as nipple sparing mastectomy, and further research is needed to discover if it can be a viable alternative for patients who are not appropriate surgical candidates.

Peek et al. (2017) conducted a systematic reviews and meta-analysis of literature exploring minimally invasive ablative techniques in the treatment of breast cancer. A total of sixty-three studies were included, totaling 1608 patients. The studies included evaluated the role of ablative techniques in the treatment of breast cancer and included ten patients or more. Minimally invasive ablative techniques included were radiofrequency ablation, high intensity focused ultrasound ablation, cryo-ablation, laser ablation, or MWA. Fifty studies reported on the number of patients with complete ablation as found on histopathology. The top performing ablative techniques with the highest rate of complete ablation achieved was radiofrequency ablation (87.1%, 491/564) and MWA (83.2%, 89/107). MWA had the most often reported short-term complications (14.6%, 21/144). Laser ablation had the highest rate of recurrence (10.7%, 11/103). The authors concluded that minimally invasive ablative techniques appear to successfully induce coagulative necrosis in breast cancer with a low side effect profile; however, larger RCTs are needed to confirm these findings.

Dooley et al. (2010) conducted a review of four clinical studies that evaluated MWA for preoperative treatment of breast tumors ranging in ultrasound-measured size from 0.8 to 7.8 cm. The authors found the initial phase 1 study, 8 of 10 (80%) participants receiving one low dose of MWA prior to mastectomy had a partial tumor response. Partial tumor response was identified by ultrasound measurements of tumor volume reduction or by pathologic cell kill. In the phase 2 study, the MWA dose was increased to stimulate 100% pathologic tumor cell kill for invasive carcinoma prior to breast-conserving surgery. The first RCT the authors analyzed comprised of participants with early-stage invasive breast cancer, 34 patients received MWA before surgery and 41 received only surgery. Positive margins were found in 10% (4 of 41 controls) compared with 0% (0 of 34) in the experimental group (p=0.13). The second RCT the authors analyzed consisted of participants with large breast tumors that resulted in a median reduction of tumor volume based on ultrasound measurements was 88.4% (n=14) for those who received MWA and chemotherapy, compared to 58.8% (n=10) reduction in those who received chemotherapy alone. Limitations of all studies analyzed include small numbers of participants. The authors concluded that wide-field adaptive phased-array MWA can be safely administered in a preoperative setting, and data from randomized studies suggest both a reduction in positive tumor margins as a heat-alone treatment for early-stage breast cancer, and a reduction in tumor volume when used in combination with anthracycline-based chemotherapy for patients with large breast cancer tumors. Larger randomized studies are required to verify these conclusions.

Vargas et al. (2004) reported a dose-finding study conducted as part of an Investigational Device Exemption (IDE) trial on 25 subjects with a mean tumor diameter of 1.8 cm. Study subjects underwent microwave thermotherapy at various doses before undergoing surgical resection of breast cancer to determine whether the use of thermotherapy before breast conserving surgery could potentially reduce the incidence of positive surgical margins, and thus the need for re-excision. Tumoricidal temperatures (> 43°C) were reached in 23 patients (92%), resulting in pathologic necrosis

achieved in 17 (68%) patients and complete necrosis in two patients. Univariate linear regression predicts that peak tumor temperatures of 47.4°C and 49.7°C cause a 50% tumor response and a 100% tumor response, respectively. The authors concluded that thermotherapy causes tumor necrosis and can be performed safely with minimal morbidity, with the degree of tumor necrosis as a function of the thermal dose. Future studies need to evaluate the impact of high doses of thermotherapy on margin status and complete tumor ablation.

Gardner et al. (2002) published on the results of a pilot study of focused microwave phased array thermotherapy in the treatment of 10 patients with primary breast carcinomas beneath the skin ranging from 1 to 8 cm in maximum clinical size. After focused microwave phased array treatment with a mean peak tumor temperature was 44.9 °C, all patients underwent mastectomy. Five to eighteen days after MWA the participants' tumors were measured via ultrasound to reveal a significant reduction in tumor size (mean, 41%) in 6 (60%) of 10 patients, and a significant tumor response based on necrosis and apoptosis measurements in 2 (20%) of 10 patients. The authors concluded that MWA can be safely administer with sufficient skin cooling techniques and that larger RCTs focusing increased tumor thermal dose efficacy studies should be investigated.

National and Specialty Organizations

The American Society of Breast Surgeons (ASBS) (2018) published a consensus guideline on transcutaneous and percutaneous methods of treating breast cancer. The guidelines indicated that these treatments are investigational, are not currently FDA approved and are therefore not recommended except in clinical trials.

The National Comprehensive Cancer Network (NCCN) (v 3.2024) Breast Cancer Clinical Practice Guidelines in Oncology does not address the use of MWA as a treatment option for breast cancer.

The National Cancer Institute (NCI) (2023) does not mention microwave thermotherapy as a treatment option for breast cancer in the NCI Breast Cancer Treatment PDQ Health Professional Version.

CODING & BILLING INFORMATION

CPT (Current Procedural Terminology) Code

Code	Description
19499	Unlisted procedure, breast [when specified as focused microwave thermotherapy for breast cancer]

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

APPROVAL HISTORY

08/14/2024	Policy reviewed and updated. No changes in coverage criteria. Updated references. IRO reviewed by a practicing physician board certified in Hematology/Oncology July 2024.
08/09/2023	Policy reviewed and updated. No changes in coverage criteria. Updated references.
08/10/2022	Policy reviewed and updated. No changes in coverage criteria. Updated references.
08/11/2021	Policy reviewed and updated. No changes in coverage criteria. Updated references.
09/16/2020	New Policy. IRO Peer Review by practicing physician board-certified in Oncology/Hematology September 2020.

REFERENCES

1. American Society of Breast Surgeons. Consensus guideline on the use of transcutaneous and percutaneous methods for the treatment of benign and malignant tumors of the breast. Published October 16, 2018. Accessed June 2024. https://www.breastsurgeons.org/.
2. Centers for Medicare and Medicaid Services (CMS). Medicare coverage database. Accessed June 2024. https://www.cms.gov/medicare-coverage-database/search.aspx.
3. Dooley WC, Vargas HI, Fenn AJ, et al. Focused microwave thermotherapy for preoperative treatment of invasive breast cancer: A review of clinical studies. Ann Surg Oncol. 2010; 17(4):1076-1093. doi: 10.1245/s10434-009-0872-z.

4. Gardner RA, Vargas HI, Block JB, et al. Focused microwave phased array thermotherapy for primary breast cancer. Ann Surg Oncol. 2002 May;9(4):326-32. doi: 10.1007/BF02573866.
5. Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. Updated October 2, 2023. Literature Review Current through May 2024. Accessed June 26, 2024. http://www.uptodate.com.
6. National Cancer Institute (NCI). Breast Cancer Treatment (PDQ) Health Professional Version. Updated January 19, 2024. Accessed June 26, 2024. https://www.cancer.gov/.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines: Breast Cancer (v 3.2024). Updated June 17, 2024. Accessed June 26, 2024. https://www.nccn.org/guidelines/category_1/.
8. Peek MCL, Ahmed M, Napoli A, Usiskin S, Baker R, Douek M. Minimally invasive ablative techniques in the treatment of breast cancer: a systematic review and meta-analysis. Int J Hyperthermia. 2017 Mar;33(2):191-202. doi: 10.1080/02656736.2016.1230232. PMID: 27575566.
9. Taghian A, Merajver SD. Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer. Updated January 25, 2024. Literature Review Current through May 2024. Accessed June 26, 2024. http://www.uptodate.com.
10. Vargas HI, Dooley WC, Gardner RA, et al. Focused microwave phased array thermotherapy for ablation of early-stage breast cancer: Results of thermal dose escalation. Ann Surg Oncol. 2004 Feb;11(2):139-46. doi: 10.1245/aso.2004.03.059. PMID 14761916.
11. Yu J, Han ZY, Li T, et al. Microwave Ablation Versus Nipple Sparing Mastectomy for Breast Cancer ≤5 cm: A Pilot Cohort Study. Front Oncol. 2020 Oct 7; 10:546883. doi: 10.3389/fonc.2020.546883. PMID: 33117685; PMCID: PMC7576845.
12. Zhou W, Yu M, Pan H, et al. Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer. J Immunother Cancer. 2021 Apr;9(4): e002343. doi: 10.1136/jitc-2021-002343. PMID: 33795388; PMCID: PMC8021888.